Scarica l'app Stockscreener
0.00
100.00%
-14.49
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché FOLD Giù?
Forum
Previsione
Amicus Therapeutics Inc Borsa (FOLD) Ultime notizie
BioMarin Pharmaceutical (BMRN)’s Alesta Deal Adds New Growth Potential in Rare Diseases - Yahoo Finance
FOLD Q4 2025 Earnings: EPS Misses Consensus by 94.35% as Company Reports Near-Breakeven ResultsPost-Earnings Drift - vinanet.vn
Asia Pacific Imiglucerase Market 2026-2033: Growth Overview, - openPR.com
Goldman Sachs (FOLD) filing shows no beneficial stake in Amicus stock - Stock Titan
BioMarin Targets Faster Deleveraging as Amicus Deal Expands Rare-Disease Growth - MarketBeat
FOLD Q4 2025 Earnings: EPS Misses Consensus by 94% as Profit Narrows to $0.005Buyback Announcement Report - vinanet.vn
Amicus Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - reveliolabs.com
Amicus Therapeutics Q4 2025 Earnings: EPS Misses Estimates by a Wide Margin Despite Narrow LossEarnings Cycle Report - vinanet.vn
Amicus Therapeutics Reports 2025 Financial Results, Merger With BioMarin, and Key Pipeline Updates - Minichart
BioMarin (BMRN) details Amicus 2025 results and $14.50-per-share merger terms - Stock Titan
Our Origin Story - BioMarin Pharmaceutical
Amicus Therapeutics Inc (FOLD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Amicus Therapeutics Inc (FOLD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Amicus Therapeutics (FOLD) Holds Steady at $14.49 Amid Consolidation PhaseSpring Pattern - dars.gov.et
Amicus Therapeutics Inc (FOLD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Amicus Therapeutics Q2 2025 Earnings Preview - MSN
Amicus Therapeutics Stock (US03152W1099): valuation picture in focus for biotech name FOLD - ad-hoc-news.de
May layoffs hit nearly 7,000, with most cuts from Takeda, BioNTech - BioSpace
BioMarin Pharmaceutical's Revenue Guidance Boost Reflects Pipeline Progress and Acquisition GrowthPost-Announcement Reaction - po-news-eg.net
Amicus Therapeutics Holds Steady at $14.49 as Key Levels Define Trading RangeAAII Bullish - DonanımHaber
Amicus Therapeutics (FOLD) Holds Steady at $14.49 as Traders Eye Key Resistance LevelFloat Adjusted Cap - dars.gov.et
John Paulson’s fund initiates Amicus Therapeutics position, dumps SOLS among Q1 moves - MSN
Amicus Therapeutics (FOLD) Holds Steady Near Support as Biotech Sector Waits for CatalystEarnings Breakout Stocks - dars.gov.et
Amicus Therapeutics stock (US03152W1099): analysts see limited upside after strong run - AD HOC NEWS
Are Amicus Therapeutics (FOLD) and Autoliv (ALV) Overlooked Opportunities - Kavout
Paulson & Co. Acquires Amicus Therapeutics (FOLD) and Exits Solstice Advanced Materials (SOLS) - GuruFocus
Barclays holds 17.8M Amicus shares (NASDAQ: FOLD), 5.65% stake - Stock Titan
Amicus Therapeutics stock (US03152W1099): Biotech focused on rare diseases - AD HOC NEWS
BioMarin cuts 58 jobs at Amicus HQ in Princeton - NJBIZ
FOLD SEC FilingsAmicus Therapeut 10-K, 10-Q, 8-K Forms - Stock Titan
BioMarin consolidates staff at Amicus HQ after closing $4.8B deal for rare disease peer - Fierce Pharma
Goldman Sachs (FOLD) discloses 16.78M shares, 5.3% ownership (Schedule 13G) - Stock Titan
Fabry Disease Treatment Market to Reach USD 3,530.5 Million - openPR.com
BioMarin Q1 earnings miss, sales beat, '26 revenue guidance raised - MSN
Amicus Therapeutics (Delisted) | SCHEDULE 13G: Others - Moomoo
UBS Group-affiliated funds hold 17.14M shares in Amicus Therapeutics (NASDAQ: FOLD) - Stock Titan
[15-12G] AMICUS THERAPEUTICS, INC. SEC Filing - Stock Titan
Which Is a Better Investment, AnaptysBio, Inc. or Amicus Therapeutics, Inc. Stock? - AAII
BioMarin: 'Strong Buy' On VOXZOGO Expansion And Amicus Acquisition (NASDAQ:BMRN) - Seeking Alpha
BioMarin acquires Amicus Therapeutics for $4.8bn - MSN
MSN Money - MSN
BioMarin to buy rare disease drugmaker Amicus Therapeutics for $4.8B - MSN
BioMarin beats estimates, raises guidance on Amicus deal By Investing.com - Investing.com South Africa
BioMarin beats estimates, raises guidance on Amicus deal - Investing.com
BioMarin Reports First Quarter 2026 Financial and Operating Results - Santa Maria Times
UBS Group AG Grows Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
CM Management LLC Has $5.27 Million Stock Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
0.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):